Key result
Anti-HER2 targeted therapies for breast cancer are associated with significant cardiotoxicity, with early trials showing up to 27% of patients experiencing cardiac events.
Why the study?
What is the incidence and mechanism of cardiotoxicity associated with anti-HER2 therapies in patients with HER2-positive breast cancer?
What is the incidence and mechanism of cardiotoxicity associated with anti-HER2 therapies in patients with HER2-positive breast cancer?
Anti-HER2 therapies are associated with significant cardiotoxicity, necessitating careful patient selection and cardiac assessment.
No takes yet. Share an insight, caveat, or question.
Supports cardiac monitoring with anti-HER2 therapies; leaves open optimal mitigation strategies across populations.
Pondé et al. (2016) conducted a review in HER2-positive breast cancer. Anti-HER2 targeted therapies was evaluated on Cardiotoxicity. Anti-HER2 targeted therapies for breast cancer are associated with significant cardiotoxicity, with early trials showing up to 27% of patients experiencing cardiac events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: